Objectives: To describe the five Phase I Pharmacy Quality Alliance (PQA) demonstration projects and discuss lessons learned across the projects.
T he implementation of Medicare Part D has made the Centers for Medicare & Medicaid Services (CMS) one of the largest payers for prescription drugs in the world. 1 This role prompted CMS to support the formation of the Pharmacy Quality Alliance (PQA), a multistakeholder organization working to establish viable approaches for measuring and reporting pharmacy performance. The evolution of systems to report pharmacy quality is likely to quicken with the development of reliable pharmacy performance measures and establishment of mechanisms for collecting and reporting pharmacy performance. After initial work to develop a set of pharmacy quality measures, an important step in PQA's mission of improving the quality of medication use through a collaborative process was supporting five Phase I demonstration projects.
The intent of the Phase I projects was to test the feasibility of using various data sources to measure pharmacy performance and of using different approaches to reporting pharmacy performance to pharmacists. Before the Phase I demonstration projects, PQA led the development of a set of pharmacy performance measures that were calculated using pharmacy claims data or dispensing records. Pillittere-Dugan et al. 2 found that several of the measures they tested possessed some, if not all, of the properties of an ideal performance measure (relevant, feasible, and scientifically sound). That study also identified a potential problem with the measure criterion of at least 30 cases per measure in each pharmacy. Strategies for aggregating data across health and drug plans were suggested for overcoming sample size challenges. Table 1 describes the PQA-developed performance measures that were calculated and reported to pharmacists in the Phase I demonstration projects. The PQA Phase I demonstration projects were designed to test the feasibility of aggregating pharmacy claims data to calculate and report performance scores to pharmacies. Insurers, pharmacies, and other organizations associated with each demonstration project collaborated in the effort to obtain sufficient reliable data to produce and report the performance measures. The five demonstration projects included one that involved an insurer/pharmacy chain team, one that involved a pharmacy chain/medication therapy management (MTM) service coordinator team, and three that followed a coalition model involving multiple insurers and a variety of pharmacies of different ownership.
Objectives
This report seeks to describe the five Phase I PQA demonstration projects and discuss lessons learned across the demonstration projects.
Description of pqA demonstration projects
All five of the demonstration projects adopted a set of objectives that were developed by working with PQA. However, each of the five demonstration projects had the flexibility to address the objectives in the manner that best fit their situation. The main objectives of the demonstration projects were to (1) create an electronic pharmacy performance report that provided performance information on individual pharmacies for comparisons with other pharmacies, (2) identify obstacles encountered in creating the reporting system and provide recommendations on ways to overcome the obstacles, (3) obtain feedback from pharmacy staff and pharmacy managers/owners on the reporting system, and (4) conduct statistical analyses to determine the proportion of pharmacies with sufficient number of cases per measure to create reliable estimates of performance scores and determine the distribution of scores on an initial set of PQA measures across a mix of pharmacies.
In June 2008, PQA announced that five Phase I projects had been selected after a competitive review process. A Phase I kickoff meeting was held in July 2008. Although each of the projects started at that time, variation in study design and obstacles resulted in project completion being somewhat staggered during mid-to late 2009. The principal investigators of the Phase I demonstration projects presented their findings at the PQA annual meeting in Washington, DC, on November 9, 2009. The five Phase I PQA demonstration projects, which are identified by the state in which they primarily operated, are described below. A list of contacts for additional information on the demonstration projects is available in Appendix 1 (elec-
At a Glance
Synopsis: Community pharmacies from five states participating in Phase I Pharmacy Quality Alliance (PQA) demonstration projects showed considerable variation in pharmacy performance scores, and some pharmacies did not have enough patients taking medications that were included in specific performance measures. Among other objectives, the PQA demonstration projects sought to create an electronic pharmacy performance report that provided performance information on individual pharmacies for comparisons with other pharmacies and identify obstacles encountered in creating the reporting system and provide recommendations on ways to overcome the obstacles. The demonstration projects showed that calculating pharmacy performance scores is feasible and that Webbased pharmacy performance reports can be created to provide feedback to community pharmacists. Purdue University School of Pharmacy and Pharmaceutical Sciences collaborated with the Regenstrief Institute and the Indiana Health Information Exchange to create the pharmacy performance scores, which were posted on the Indiana Pharmacy Compare website. Pharmacists could view their pharmacy's performance scores and compare them with the average score from all participating pharmacies. If the pharmacy performance score was not as desirable as the average score, then an icon indicated that the performance measure was an improvement opportunity. In addition, the reporting website ranked the participating pharmacies based on their scores. The last column on the report was a pharmacy loyalty score, which was calculated by using a denominator of the number of people who qualified for each performance measure and a numerator of how many of those people had all of their prescriptions for that medication dispensed at the pharmacy.
In addition to the pharmacy report, educational materials were posted on the Indiana Pharmacy Compare website. Pharmacists could access a PowerPoint presentation that gave an overview of pharmacy quality improvement and the PQA demonstration project. A frequently asked questions section and supplemental reading materials also were available. Using an online survey on the Indiana Pharmacy Compare website, pharmacists could provide feedback regarding the performance reports. Of the 87 participating pharmacists, 37 responded to the survey (42.5% response rate). In addition, they could learn about which drug classes were included to calculate each performance score by hovering their mouse over an icon. Their numerator and denominator also were displayed so that the pharmacist could understand why they received the score. An icon on the report indicated whether they scored better or worse than the average. Pharmacist education was offered before the website was available to the pharmacists using a 1-hour program created by the Collaborative Education Institute that discussed quality improvement in pharmacy. The program, which also was used by the Wisconsin project, was titled Advancing Pharmacy Practice through Performance Measurement: A Primer. After pharmacists had viewed their performance report on the website, they were directed to an online survey, through which 35 pharmacists provided feedback about the performance scores and the reporting website. The performance scores were displayed on the Outcomes website alongside an average score calculated from all of the pharmacies. In addition to the scores, the reports had a column that specified whether the desired score was high (e.g., near 100) or low (e.g., near 0). The last column in the report was a plus/minus indicator icon that indicated whether the score was above or below the system average, respectively.
Outcomes developed pharmacist training and gathered feedback from the pharmacists. Outcomes and Kerr Drug conducted three PQA training webinars to introduce the PQA reports to pharmacists. The webinars included a general overview of the PQA demonstration projects, an overview of the performance measures, a description of the patient survey, details on the specific strengths and weaknesses of the model created to generate the quality reports (e.g., attribution, small numbers), and an introduction to accessing and using the reports available on the Outcomes website. A survey was distributed to the clinical team pharmacists who were involved in the project. The survey consisted of four open-response questions such as "Do you believe the reports are accurate?'' and "If you came to believe the reports were accurate, would you care or have the ability to do something about them?" Pharmacists were asked to complete this survey and return via fax. pennsylvania Highmark Blue Cross Blue Shield worked in collaboration with CECity, Inc., and Rite Aid pharmacies in western Pennsylvania. A total of 50 Rite Aid pharmacies in five counties, with about 120 pharmacists, participated in the project. Two hours of live training were delivered to the participating pharmacists. The training topics included an overview of quality measurement, a description of the PQA measure set, and an orientation to the demonstration project procedures.
Highmark used the PQA/National Committee for Quality Assurance (NCQA) technical specifications to calculate the performance measures using data from Rite Aid pharmacies and then supplied the results to CECity. The measures were calculated on a quarterly basis using 12 months of data for each quarterly report. CECity adapted their existing Lifetime platform to develop, maintain, and deliver the performance reports to the Rite Aid pharmacies. The pharmacy performance scores were posted for three consecutive quarters on the reporting website. Each time the report was posted, pharmacists could view their pharmacy's scores for each performance measure and compare their pharmacy against the average score for the other Rite Aid pharmacies in their region (n = 4-8 pharmacies per region) or against the average scores of the entire project population (n = 50). The second and third posting included an icon that indicated whether the score had changed since the last posting, what direction the score changed, and whether the change was in the desired direction.
Rite Aid hosted an electronic feedback survey tool that allowed pharmacists to respond to a brief electronic survey upon reviewing each performance report for their pharmacy. Feedback was elicited after each round of the reporting process. The survey consisted of both open-ended responses eliciting qualitative feedback and a number of items scored on a Likerttype scale, in order to elicit more quantitative feedback.
Wisconsin
The Pharmacy Society of Wisconsin coordinated the project and recruited pharmacies and payers through the Wisconsin Pharmacy Quality Collaborative (WPQC). WPQC is a statewide consortium of community-based pharmacists and health plan/ purchaser representatives dedicated to creating a qualitybased pay-for-performance business model that aligns incentives for both pharmacists and payers in the private and public sector. 3 The University of Wisconsin Center for Health Systems Research and Analysis (CHSRA) arranged business associate agreements, obtained and managed pharmacy claim and eligibility data, and calculated pharmacy performance scores. CHSRA also designed the performance reports and created and hosted the project website. The reporting website contained five main content sections. The first four sections contained ExpEriEncE PQA DEMONSTRATION PROJECTS pharmacist education resources, including an introduction with link to the Collaborative Education Institute's PQA program, a section defining the quality indicators, a section about the reports, and frequently asked questions. The fifth section contained the actual performance report for each specific pharmacy. The pharmacy performance report showed the performance score for the individual pharmacy and a comparison performance score of the average of all participating Wisconsin pharmacies. The report also gave the pharmacy a percentile ranking. Rankings in the top quartile were flagged with a star, and rankings in the bottom quartile were flagged with an exclamation point.
The Performance scores were calculated for all Wisconsin pharmacies serving Medicaid. A total of 41 pharmacists representing 19 pharmacies were invited to give feedback on performance reports. The 19 pharmacies were selected based on having denominators of sufficient size for 10 or more of the performance reports. Representatives from the three participating payers also were invited to provide feedback. Ten pharmacists and two payer representatives submitted answers to the feedback questions.
reported pharmacy performance
Pharmacy performance scores showed considerable variation across the pharmacies and projects (Table 2 ). For example, the mean rating of proportion of days covered (PDC) for beta blockers across the five projects ranged from 46% to 71%. Further, the minimum among all pharmacies in the five demonstration projects was 15%, while the maximum was 87%. This level of variation shows that these performance scores have room for improvement. The PDC and Gap in Therapy measures reflect patient adherence for different classes of chronic medications. Although pharmacists could act to improve patient adherence, these numbers show that our current pharmacy system does not readily support pharmacists in such a role. Future work by PQA and its partners will address pharmacists' impact on patient adherence.
Because these performance measures are relatively new, accepted benchmarks have not been established. For example, the projects reported that, on average, 13% to 28% of elderly patients were taking a medication considered to be high risk for older adults (i.e., Beers criteria). A target level for the percentage of older adults who can take these medications safely has not been set. Although some people would recommend that no older patient should take one of these medications, dis- 4 Future research can address this question. In the absence of a benchmark, these numbers represent opportunities for pharmacists to verify that the highrisk medication is the best choice for the patient.
The results for the suboptimal diabetes treatment measure show that, on average, 22% to 32% of a pharmacy's patients with a drug for diabetes and for hypertension were not taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), which would follow treatment guidelines. Again, these numbers reflect opportunities for pharmacists to work with patients and physicians to ensure patients are receiving drug therapy that is consistent with accepted guidelines. Although pharmacists ultimately will need to work with individual patients, every pharmacy is likely to need a system that supports pharmacists in addressing their performance. The PQA Phase I projects described here did not assess the ability of pharmacies to improve their performance scores. Future Phase II activities, expected to begin in 2010, are designed to address those issues.
Discussion of lessons learned
Common themes were found in the pharmacist feedback from all five projects. Many pharmacists were curious about the reports and provided feedback. In general, they liked being able to see how their pharmacy compared with other pharmacies within the project. Some also expressed the sentiment that they would prefer that their pharmacy be evaluated on concepts such as safety and adherence rather than volume of prescriptions dispensed. However, many pharmacists were interested in getting individual patient reports that identified specific patients not meeting performance cutoffs. Such reports would allow pharmacists to target patients in need of pharmacy care services while working to improve their pharmacy's performance scores. The Wisconsin project included strategies that pharmacists can use to change the value of each group of performance measures. Even with this additional information, some pharmacists desired even greater direction on how to improve their pharmacy's performance. A more fundamental challenge was faced by one project in that the pharmacists could not view the Web-based reports because the pharmacies did not have Internet access. Although a workable solution was created, pharmacists in such pharmacies will have a challenge to interact readily with online pharmacy performance reports and other quality improvement activities that are supported by interactive media.
One common response was in regard to the "ideal" score for an indicator. Pharmacists were confused about whether a high or low score was optimal in each indicator. All of the demonstration projects included a visual representation (e.g., icon) showing how a pharmacy compared with the average scores, but some confusion still occurred. The PDC indicators were ideally high, whereas all other indicators were preferably low.
The educational material provided to the participating pharmacists varied from live training to Web-based tutorials and continuing education programs. The live training was viewed positively by the pharmacists; however, it is the most expensive approach. Support existed among pharmacists for interactive Web-based training about quality scoring and reporting. Static online training is flexible in that the pharmacists can access it when they have time. However, the absence of an interactive capacity can limit the pharmacists' ability to ask questions. In addition to feedback on how to deliver the training, some comments about content were made by pharmacists. One issue was to have more detail on the performance measures. For example, several pharmacists stated that they wanted to know the medications included in each measure. The websites developed by the Wisconsin and Pennsylvania projects included detailed information about how each performance measure was calculated and the drugs that were included in it.
The calculation of the pharmacy performance scores varied somewhat across the five demonstration projects. One issue was the need for an up-to-date list of National Drug Codes (NDCs) in order to accurately create scores as new NDC numbers emerge over time. Several projects had issues related to NDCs, such as higher nonadherence rates resulting from patients switching to new prescriptions with unrecognized NDCs. Therefore, the specifications of the pharmacy performance measures will need to be regularly updated to accommodate products with new NDCs that should be included in the measures. PQA recently implemented a process for annual updates of the technical specifications and NDC lists for the performance measures. This should provide a consistent and up-todate list of drugs to be included in each measure.
Another issue for the performance scores across all five projects was low denominators (i.e., number of cases) for some of the measures. For example, all five projects found that participating pharmacies had very low denominators in the asthma controller therapy measure. Thus, the majority of participating pharmacies in all five projects had too few patients to report reliable performance scores for this measure. The standard set by NCQA for reliable measure reporting is 30 cases in the denominator. The Highmark project found that 47% of the calculated performance scores were ineligible for reporting within this guideline across all of the quality measures. The University of Iowa project found that 31.9% of calculated performance scores were ineligible for reporting because the number of cases was insufficient. To increase the number of evaluable pharmacies, one could either lower the threshold for the acceptable number of cases for a performance measure or aggregate data from multiple payers.
The Wisconsin and Iowa projects included data from more than one payer but still found that some measures did not reach the minimum threshold of 30 patients per measure. After exploring this threshold issue, the University of Wisconsin noted that the number of pharmacies for which reliable scores could be calculated would be increased dramatically when the minimum denominator size changed from 30 to 1. For example, for the adherence measures related to thiazolidinediones, the number of pharmacies that were evaluable increased from 16 to 950 when the minimum denominator size was changed from 30 cases to 1 case. For the adherence measures related to ACE inhibitors, the number of evaluable pharmacies increased from
